HRP20211478T1 - Imunoterapijski režimi doziranja koji obuhvaćaju pomalidomid i anti-cs1 antitijelo za liječenje raka - Google Patents
Imunoterapijski režimi doziranja koji obuhvaćaju pomalidomid i anti-cs1 antitijelo za liječenje raka Download PDFInfo
- Publication number
- HRP20211478T1 HRP20211478T1 HRP20211478TT HRP20211478T HRP20211478T1 HR P20211478 T1 HRP20211478 T1 HR P20211478T1 HR P20211478T T HRP20211478T T HR P20211478TT HR P20211478 T HRP20211478 T HR P20211478T HR P20211478 T1 HRP20211478 T1 HR P20211478T1
- Authority
- HR
- Croatia
- Prior art keywords
- dose
- administered
- days
- elotuzumab
- orally
- Prior art date
Links
- 229960000688 pomalidomide Drugs 0.000 title claims 10
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 title claims 10
- 206010028980 Neoplasm Diseases 0.000 title claims 4
- 201000011510 cancer Diseases 0.000 title claims 2
- 230000001024 immunotherapeutic effect Effects 0.000 title 1
- 229960004137 elotuzumab Drugs 0.000 claims 17
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 9
- 229960003957 dexamethasone Drugs 0.000 claims 9
- 238000011285 therapeutic regimen Methods 0.000 claims 7
- 208000034578 Multiple myelomas Diseases 0.000 claims 6
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 6
- 230000003442 weekly effect Effects 0.000 claims 5
- 238000002648 combination therapy Methods 0.000 claims 4
- 229960004942 lenalidomide Drugs 0.000 claims 3
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 3
- 238000011282 treatment Methods 0.000 claims 3
- 238000011221 initial treatment Methods 0.000 claims 2
- 101710085938 Matrix protein Proteins 0.000 claims 1
- 101710127721 Membrane protein Proteins 0.000 claims 1
- 102100032965 Myomesin-2 Human genes 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 210000004180 plasmocyte Anatomy 0.000 claims 1
- 230000002195 synergetic effect Effects 0.000 claims 1
- 230000005748 tumor development Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562185968P | 2015-06-29 | 2015-06-29 | |
| US201562239965P | 2015-10-11 | 2015-10-11 | |
| US201562262574P | 2015-12-03 | 2015-12-03 | |
| EP16738609.3A EP3313528B1 (en) | 2015-06-29 | 2016-06-28 | Immunotherapeutic dosing regimens comprising pomalidomide and an anti-cs1 antibody for treating cancer |
| PCT/US2016/039723 WO2017003990A1 (en) | 2015-06-29 | 2016-06-28 | Immunotherapeutic dosing regimens comprising pomalidomide and an anti-cs1 antibody for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211478T1 true HRP20211478T1 (hr) | 2021-12-24 |
Family
ID=56409706
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211478TT HRP20211478T1 (hr) | 2015-06-29 | 2016-06-28 | Imunoterapijski režimi doziranja koji obuhvaćaju pomalidomid i anti-cs1 antitijelo za liječenje raka |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US10925867B2 (enExample) |
| EP (2) | EP3950065A1 (enExample) |
| JP (1) | JP6754785B2 (enExample) |
| CN (1) | CN107949425A (enExample) |
| BR (1) | BR112017027692A2 (enExample) |
| CA (1) | CA2990478A1 (enExample) |
| CY (1) | CY1124543T1 (enExample) |
| DK (1) | DK3313528T3 (enExample) |
| EA (1) | EA035888B1 (enExample) |
| ES (1) | ES2886657T3 (enExample) |
| HR (1) | HRP20211478T1 (enExample) |
| HU (1) | HUE056491T2 (enExample) |
| LT (1) | LT3313528T (enExample) |
| MX (1) | MX391581B (enExample) |
| PL (1) | PL3313528T3 (enExample) |
| PT (1) | PT3313528T (enExample) |
| RS (1) | RS62352B1 (enExample) |
| SI (1) | SI3313528T1 (enExample) |
| SM (1) | SMT202100567T1 (enExample) |
| WO (1) | WO2017003990A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7120763B2 (ja) * | 2014-08-22 | 2022-08-17 | セルジーン コーポレイション | 免疫調節化合物を抗体と併用する多発性骨髄腫の治療方法 |
| ES2886657T3 (es) * | 2015-06-29 | 2021-12-20 | Bristol Myers Squibb Co | Regímenes de dosificación inmunoterapéutica que comprenden pomalidomida y un anticuerpo anti-CS1 para el tratamiento de cáncer |
| EP3488851A1 (en) * | 2018-10-03 | 2019-05-29 | AVM Biotechnology, LLC | Immunoablative therapies |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA204125A (en) | 1920-09-21 | Sylvester Pratt Edwin | Gramophone operated toy | |
| US819826A (en) | 1905-12-14 | 1906-05-08 | Frank R Welcher | Stanchion. |
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
| US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| WO1998042752A1 (en) | 1997-03-21 | 1998-10-01 | Brigham And Women's Hospital Inc. | Immunotherapeutic ctla-4 binding peptides |
| EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| CA2356215C (en) | 1998-12-23 | 2015-11-24 | Pfizer Inc. | Human monoclonal antibodies to ctla-4 |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| US6262094B1 (en) | 1999-02-22 | 2001-07-17 | Bristol-Myers Squibb Company | C-21 modified epothilones |
| US7629360B2 (en) | 1999-05-07 | 2009-12-08 | Celgene Corporation | Methods for the treatment of cachexia and graft v. host disease |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| WO2001014424A2 (en) | 1999-08-24 | 2001-03-01 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| WO2001054732A1 (en) | 2000-01-27 | 2001-08-02 | Genetics Institute, Llc. | Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof |
| US7041499B2 (en) | 2001-12-12 | 2006-05-09 | University Of North Texas Health Science Center | Immuno activation of CS1 receptor in natural killer cells to inhibit tumor cell growth |
| US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| SI1505973T1 (sl) * | 2002-05-17 | 2010-06-30 | Celgene Corp | Kombinacija za zdravljenje multiplega mieloma |
| ES2744275T3 (es) | 2002-10-17 | 2020-02-24 | Genmab As | Anticuerpos monoclonales humanos contra CD20 para su uso en el tratamiento de esclerosis múltiple |
| US7709610B2 (en) | 2003-05-08 | 2010-05-04 | Facet Biotech Corporation | Therapeutic use of anti-CS1 antibodies |
| US20050025763A1 (en) | 2003-05-08 | 2005-02-03 | Protein Design Laboratories, Inc. | Therapeutic use of anti-CS1 antibodies |
| US6958115B2 (en) | 2003-06-24 | 2005-10-25 | The United States Of America As Represented By The Secretary Of The Navy | Low temperature refining and formation of refractory metals |
| DK2161336T4 (en) | 2005-05-09 | 2017-04-24 | Ono Pharmaceutical Co | Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies |
| SI2068930T1 (sl) * | 2006-08-07 | 2013-01-31 | Abbott Biotherapeutics Corp. | Sestavki in postopki, pri katerih se uporabljajo anti-CS1 protitelesa za zdravljenje multiplega mieloma |
| WO2008019379A2 (en) | 2006-08-07 | 2008-02-14 | Pdl Biopharma, Inc. | Use of allogeneic effector cells and anti-cs1 antibodies for selective killing of multiple myeloma cells |
| CA2660356C (en) * | 2006-08-07 | 2016-04-05 | Pdl Biopharma, Inc. | Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies |
| PT2068930E (pt) * | 2006-08-07 | 2012-10-23 | Abbott Biotherapeutics Corp | Composições e métodos utilizando anticorpos anti-cs1 para tratar mieloma múltiplo |
| KR20110096536A (ko) | 2008-10-31 | 2011-08-30 | 애보트 바이오테라퓨틱스 코포레이션 | 희귀 림프종의 치료를 위한 항ｃｓ1 항체의 용도 |
| SMT201700097T1 (it) | 2009-05-19 | 2017-03-08 | Celgene Corp | Formulazioni di 4-ammino-2-(2,6-diossopiperidin-3-il)isoindolin-1,3-dione |
| EP2493486A1 (en) | 2009-10-30 | 2012-09-05 | University Of Arkansas For Medical Science | Use of autologous effector cells and antibodies for treatment of multiple myeloma |
| WO2011053321A1 (en) | 2009-10-30 | 2011-05-05 | University Of Arkansas For Medical Science | Use of autologous effector cells for treatment of multiple myeloma |
| US9506481B1 (en) | 2013-01-31 | 2016-11-29 | Daniel Theobald | High force hydraulic actuator |
| US20160331698A1 (en) * | 2014-01-13 | 2016-11-17 | University Of Central Florida Research Foundation, Inc. | Fullerene compounds as antioxidant therapy |
| JP7120763B2 (ja) * | 2014-08-22 | 2022-08-17 | セルジーン コーポレイション | 免疫調節化合物を抗体と併用する多発性骨髄腫の治療方法 |
| WO2016070089A2 (en) | 2014-10-31 | 2016-05-06 | Abbvie Biotherapeutics Inc. | Anti-cs1 antibodies and antibody drug conjugates |
| ES2886657T3 (es) * | 2015-06-29 | 2021-12-20 | Bristol Myers Squibb Co | Regímenes de dosificación inmunoterapéutica que comprenden pomalidomida y un anticuerpo anti-CS1 para el tratamiento de cáncer |
-
2016
- 2016-06-28 ES ES16738609T patent/ES2886657T3/es active Active
- 2016-06-28 WO PCT/US2016/039723 patent/WO2017003990A1/en not_active Ceased
- 2016-06-28 CN CN201680049473.8A patent/CN107949425A/zh active Pending
- 2016-06-28 EP EP21187060.5A patent/EP3950065A1/en not_active Withdrawn
- 2016-06-28 EA EA201890035A patent/EA035888B1/ru not_active IP Right Cessation
- 2016-06-28 HR HRP20211478TT patent/HRP20211478T1/hr unknown
- 2016-06-28 SI SI201631351T patent/SI3313528T1/sl unknown
- 2016-06-28 JP JP2017568264A patent/JP6754785B2/ja active Active
- 2016-06-28 PT PT167386093T patent/PT3313528T/pt unknown
- 2016-06-28 BR BR112017027692A patent/BR112017027692A2/pt not_active Application Discontinuation
- 2016-06-28 MX MX2017015765A patent/MX391581B/es unknown
- 2016-06-28 LT LTEPPCT/US2016/039723T patent/LT3313528T/lt unknown
- 2016-06-28 CA CA2990478A patent/CA2990478A1/en active Pending
- 2016-06-28 US US15/738,412 patent/US10925867B2/en active Active
- 2016-06-28 DK DK16738609.3T patent/DK3313528T3/da active
- 2016-06-28 PL PL16738609T patent/PL3313528T3/pl unknown
- 2016-06-28 EP EP16738609.3A patent/EP3313528B1/en active Active
- 2016-06-28 HU HUE16738609A patent/HUE056491T2/hu unknown
- 2016-06-28 RS RS20211157A patent/RS62352B1/sr unknown
- 2016-06-28 SM SM20210567T patent/SMT202100567T1/it unknown
-
2021
- 2021-01-15 US US17/150,099 patent/US20210154183A1/en not_active Abandoned
- 2021-09-28 CY CY20211100854T patent/CY1124543T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL3313528T3 (pl) | 2021-12-13 |
| EA201890035A1 (ru) | 2018-06-29 |
| HUE056491T2 (hu) | 2022-02-28 |
| CA2990478A1 (en) | 2017-01-05 |
| LT3313528T (lt) | 2021-10-11 |
| EA035888B1 (ru) | 2020-08-27 |
| MX391581B (es) | 2025-03-04 |
| MX2017015765A (es) | 2018-04-13 |
| CN107949425A (zh) | 2018-04-20 |
| JP2018522881A (ja) | 2018-08-16 |
| EP3950065A1 (en) | 2022-02-09 |
| PT3313528T (pt) | 2021-09-16 |
| EP3313528B1 (en) | 2021-08-04 |
| JP6754785B2 (ja) | 2020-09-16 |
| US20210154183A1 (en) | 2021-05-27 |
| SMT202100567T1 (it) | 2021-11-12 |
| WO2017003990A1 (en) | 2017-01-05 |
| ES2886657T3 (es) | 2021-12-20 |
| RS62352B1 (sr) | 2021-10-29 |
| CY1124543T1 (el) | 2022-07-22 |
| DK3313528T3 (da) | 2021-09-20 |
| SI3313528T1 (sl) | 2021-11-30 |
| US10925867B2 (en) | 2021-02-23 |
| US20180185348A1 (en) | 2018-07-05 |
| BR112017027692A2 (pt) | 2018-10-09 |
| EP3313528A1 (en) | 2018-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ725006A (en) | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns | |
| MX385543B (es) | Uso de un anticuerpo biespecífico para tratar cáncer de linfocitos b. | |
| ZA202107358B (en) | Method for treating alzheimer's disease | |
| RU2019109464A (ru) | Способы применения биспецифического антитела, которое распознает фактор свертывания ix и/или активированный фактор свертывания ix и фактор свертывания x и/или активированный фактор свертывания x | |
| SG10201811185YA (en) | Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii | |
| JP2016513640A5 (enExample) | ||
| JP2015532292A5 (enExample) | ||
| MX2015015735A (es) | Regimenes de dosificacion de inmunoconjugado anti-receptor en folato 1 (folr1). | |
| RU2018103064A (ru) | Комбинация ингибитора hdac и анти-pd-l1-антитела для лечения злокачественной опухоли | |
| MX2018003028A (es) | Reduccion de los niveles o de la actividad de los linfocitos t reguladores sistemicos para el tratamiento de enfermedades y lesiones del sistema nervioso central (snc). | |
| MX2009012598A (es) | Formas de dosis que comprenden vx-950 y su regimen de dosificacion. | |
| AR087356A1 (es) | Terapia de combinacion para el tratamiento de sintomas de tumores malignos de celulas b cd19que comprende inmunoconjugado maitansinoide anti-cd19 y rituximab | |
| EA201891388A1 (ru) | Ингибиторы калликреина плазмы и их применение для лечения обострения наследственного ангионевротического отека | |
| MX2021004120A (es) | Regimen de dosificacion para antagonistas de tfpi. | |
| FI3463457T3 (fi) | Pd-1-esto nivolumabilla refraktaarinen hodgkinin lymfoomassa | |
| JP2017537927A5 (enExample) | ||
| PH12021550965A1 (en) | Combination therapy for treatment of hematological diseases | |
| WO2017042633A3 (en) | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns | |
| HRP20211478T1 (hr) | Imunoterapijski režimi doziranja koji obuhvaćaju pomalidomid i anti-cs1 antitijelo za liječenje raka | |
| MX2023007826A (es) | Metodos que comprenden una dosificacion intermitente fija de cediranib. | |
| MX2022005628A (es) | Regimen de dosificacion para agentes anti-bcma. | |
| JP2018522881A5 (enExample) | ||
| FI3359572T3 (fi) | Menetelmä multippeliskleroosin hoitamiseksi | |
| RU2013126798A (ru) | Комбинированная терапия дексаметазоном | |
| Poelen | Thrombocytopenia: case report |